Tonix Pharma ( (TNXP) ) has provided an announcement.
The Company has unveiled promising preclinical results for its TNX-801 vaccine candidate at the World Vaccine Congress-Europe 2024, showcasing its safety and efficacy even in immunocompromised animals. This novel, single-dose vaccine does not spread in blood or tissues, even at doses much higher than traditional vaccines, sparking interest among investors for its potential market impact. However, forward-looking statements highlight uncertainties and risks, urging investors to tread carefully.
Find detailed analytics on TNXP stock on TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
